“Hot and cold.” The juxtaposition is a perfect illustration of passion’s heat and the iciness of manipulation. This ...

How to enjoy wine on your own terms -- beliefs we hold dear at Reverse Wine Snob. Our Ten Tenets of Reverse Wine Snobbery. If ...

From boosting gut health to preventing heart disease, there are benefits to low amounts of red wine. Here’s what you need to know If you persevered through the miserable first month of the year ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...

Each year, Rob McMillan, Executive Vice President of Silicon Valley Bank’s wine division, delivers one of the most anticipated reports on the state of the wine industry. His insights are data ...

Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectively, in a pair of new stock offerings priced Thursday ...

With an uncommon focus on white wine, Conde de los Andes’ extensive library of older vintages offers a rare glimpse into the remarkable potential of white Rioja. The winery’s nearly two miles ...

We may earn an affiliate commission from links. The best red lipsticks bolster confidence, ooze glamour, and command attention—but they’re not always for the faint of heart. “A red lip is a ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...

Maze seeks as much as $133 mln in New York IPO Backers include Alphabet's GV and Third Rock Ventures Biotech IPOs set for ramp up in coming weeks Jan 27 (Reuters) - Drug developer Maze ...